Equilibre BioPharmaceuticals Corp. — Form D/A
Equilibre BioPharmaceuticals Corp. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2022-12-01. The offering totals $6.0M, of which $6.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-12-01
- Form: D/A
- Accession: 0001831900-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $6.0M
- Amount sold: $6.0M
- Investors: 13
- Date of first sale: 2022-11-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-466233
Issuer
- Name: Equilibre BioPharmaceuticals Corp.
- CIK: 0001831900
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 430 E 29th St., NEW YORK, NY, 10016
- Phone: 332-400-0300
Officers, directors & promoters (20)
| Name | Role | Location |
|---|
| PHILIP A BARACH | Director | LOS ANGELES, CA |
| DAVID A FRIEDMAN | Director | EVANSTON, IL |
| Steven N Gordon | Director | New York, NY |
| Francois A Maisonrouge | Director | New York, NY |
| Christina A Ramirez | Director | New York, NY |
| Peter M Simon | Director | New York, NY |
| PHILIP A BARACH | Executive Officer | LOS ANGELES, CA |
| Steven N Gordon | Executive Officer | New York, NY |
| Christopher M Thorn | Executive Officer | New York, NY |
| Peter Simon | Director | Denver, CO |
| Joel Marcus | Director | South San Francisco, CA |
| David Friedman | Director | NEW HAVEN, CT |
| Philip Barach | Director | Portland, ME |
| Christopher M Thorn | Director | New York, NY |
| Francois Maisonrouge | Director | New York, NY |
| Steven Gordon | Director | New York, NY |
| Steven Gordon | Executive Officer | New York, NY |
| Samuel Waksal | Director | New York, NY |
| Samuel Waksal | Executive Officer | New York, NY |
| Sam Waksal | Executive Officer | New York, NY |
Other filings by this issuer (3)
More